Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment

被引:15
|
作者
Zhou, Zhengyuan [1 ]
Meshaw, Rebecca [1 ]
Zalutsky, Michael R. [1 ]
Vaidyanathan, Ganesan [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
single-domain antibody fragment; site-specific labeling; immuno-PET; click chemistry; HER2; HER2 RECEPTOR EXPRESSION; N-SUCCINIMIDYL; NANOBODY;
D O I
10.2967/jnumed.120.261446
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Single-domain antibody fragments (sdAbs) are promising vectors for immuno-PET; however, better methods for labeling sdAbs with F-18 are needed. Herein, we evaluate a site-specific strategy using an F-18 residualizing motif and the anti-epidermal growth factor receptor 2 (HER2) sdAb 5F7 bearing an engineered C-terminal GGC tail (5F7GGC). Methods: 5F7GGC was site-specifically attached with a tetrazine-bearing agent via thiol-maleimide reaction. The resultant conjugate was labeled with F-18 by inverse electron demand Diels-Alder cycloaddition with a trans-cyclooctene attached to 6-F-18-fluoronicotinoyl moiety via a renal brush border enzyme-cleavable linker and a PEG4 chain (F-18-5F7GGC). For comparisons, 5F7 sdAb was labeled using the prototypical residualizing agent, N-succinimidyl 3-(guanidinomethyl)5-I-125-iodobenzoate (iso-I-125-SGMIB). The 2 labeled sdAbs were compared in paired-label studies performed in the HER2-expressing BT474M1 breast carcinoma cell line and athymic mice bearing BT474M1 subcutaneous xenografts. Small-animal PET/CT imaging after administration of F-18-5F7GGC in the above mouse model was also performed. Results: F-18-5F7GGC was synthesized in an overall radiochemical yield of 8.9% +/- 3.2% with retention of HER2 binding affinity and immunoreactivity. The total cell-associated and intracellular activity for F-18-5F7GGC was similar to that for coincubated iso-(125)ISGMIB-5F7. Likewise, the uptake of F-18-5F7GGC in BT474M1 xenografts in mice was similar to that for iso-I-125-SGMIB-5F7; however, F-18-5F7GGC exhibited significantly more rapid clearance from the kidney. Small-animal PET/CT imaging confirmed high uptake and retention in the tumor with very little background activity at 3 h except in the bladder. Conclusion: This site-specific and residualizing 18F-labeling strategy could facilitate clinical translation of 5F7 anti-HER2 sdAb as well as other sdAbs for immuno-PET.
引用
收藏
页码:1624 / 1630
页数:7
相关论文
共 36 条
  • [1] Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent
    Feng, Yutian
    Zhou, Zhengyuan
    McDougald, Darryl
    Meshaw, Rebecca L.
    Vaidyanathan, Ganesan
    Zalutsky, Michael R.
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 92 : 171 - 183
  • [2] Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent
    Feng, Yutian
    Sarrett, Samantha M.
    Meshaw, Rebecca L.
    Vaidyanathan, Ganesan
    Cornejo, Mike A.
    Zeglis, Brian M.
    Zalutsky, Michael R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (22) : 15358 - 15373
  • [3] Anti-HER2 Single Domain Antibody 2Rs15d Labeled with 18F Using a Residualizing Label: Preliminary Evaluation
    Vaidyanathan, G. V.
    Zhou, Z.
    McDougald, D.
    Lahoutte, T.
    Zalutsky, M. R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S179 - S179
  • [4] Simplified 211At-labeling of internalizing proteins by preconjugation with the tin precursor of a residualizing prosthetic agent: Application to an anti-HER2 single domain antibody fragment
    Kang, Choong Mo
    Vaidyanathan, Ganesan
    McDougald, Darryl
    Zalutsky, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [5] An Anti-HER2 Nanobody Labeled with 18F Using a Residualizing Label for Assessing HER2 Status
    Vaidyanathan, G.
    McDougald, D.
    Choi, J.
    Koumarianou, E.
    Pruszynski, M.
    Osada, T.
    Lyerly, H.
    Lahoutte, T.
    Zalutsky, M. R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S102 - S102
  • [6] Labeling an anti-HER2 VHH with 18F using a residualizing prosthetic group via strain-promoted click reaction: preliminary evaluation
    Zhou, Zhengyuan
    Devoogdt, Nick
    Zalutsky, Michael
    Vaidyanathan, Ganesan
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [7] Site-specific radiolabeling of an anti-HER2 single domain antibody fragment with an 211At-labeled prosthetic agent: preliminary evaluation of a potential targeted α-particle therapeutic
    Feng, Yutian
    Sarrett, Samantha
    Meshaw, Rebecca
    Vaidyanathan, Ganesan
    Zeglis, Brian
    Zalutsky, Michael
    NUCLEAR MEDICINE AND BIOLOGY, 2022, 108 : S32 - S32
  • [8] Co-crystallisation and humanisation of an anti-HER2 single-domain antibody as a theranostic tool
    Sawmynaden, Kovilen
    Wong, Nicholas
    Davies, Sarah
    Cowan, Richard
    Brown, Richard
    Tang, David
    Henry, Maud
    Tickle, David
    Matthews, David
    Carr, Mark
    Bakrania, Preeti
    Ting, Hong Hoi
    Hall, Gareth
    PLOS ONE, 2023, 18 (07):
  • [9] Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation
    Zhou, Zhengyuan
    Vaidyanathan, Ganesan
    McDougald, Darryl
    Kang, Choong Mo
    Balyasnikova, Irina
    Devoogdt, Nick
    Ta, Angeline N.
    McNaughton, Brian R.
    Zalutsky, Michael R.
    MOLECULAR IMAGING AND BIOLOGY, 2017, 19 (06) : 867 - 877
  • [10] Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation
    Zhengyuan Zhou
    Ganesan Vaidyanathan
    Darryl McDougald
    Choong Mo Kang
    Irina Balyasnikova
    Nick Devoogdt
    Angeline N. Ta
    Brian R. McNaughton
    Michael R. Zalutsky
    Molecular Imaging and Biology, 2017, 19 : 867 - 877